Search results for "From ACP Journal Club"
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
An analysis of recent manufacturer-sponsored studies of finerenone show it to be a potentially important new treatment for patients with type 2 diabetes and albuminuric chronic kidney disease (CKD), although it poses risk for serious hyperkalemia, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/05/13/6.htm
13 May 2022
Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class
The results of this individual-patient data meta-analysis suggest that angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers should be first-line antihypertensive agents in patients with prediabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/04/08/7.htm
8 Apr 2022
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
https://diabetes.acponline.org/archives/2022/03/11/7.htm
11 Mar 2022
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
This industry-funded trial of tirzepatide, a unimolecular dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, heralds a new era of “twincretins” in diabetes management, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/11/12/6.htm
12 Nov 2021
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/10/08/7.htm
8 Oct 2021
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021
One-step screening approach detected more gestational diabetes than two-step approach but did not improve clinical outcomes
A screening approach that finds more cases of gestational diabetes without improving patient outcomes introduces considerable burden and costs to patients, clinicians, and medical systems, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/08/13/6.htm
13 Aug 2021
In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y
Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021